866-997-4948(US-Canada Toll Free)

Epilepsy-Market Insights, Epidemiology and Market Forecast-2025

Published By :

DelveInsight

Published Date : Sep 2017

Category :

Pharmaceutical

No. of Pages : 127 Pages

DelveInsights Epilepsy-Market Insights, Epidemiology and Market Forecast-2025 report provides an overview of the Epilepsy, epidemiology and market trend of the Epilepsy for the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report covers the therapeutics market revenue, treatment practice/algorithm and forecasted market size of Epilepsy from 2017 to 2025 segmented by seven major markets. In addition, the report also includes the forecasted epidemiology of Epilepsy till 2025.The Report also covers market drivers, market barriers and unmet medical need.

Our report provides the subtype specific prevalent population i.e. Focal Epilepsy, Generalized Epilepsy and Unclassified Epilepsy. In addition, the report also covers the prevalent cases of TSC associated Epilepsy in 6MM (excluding Japan). According to DelveInsight, the prevalent population of Epilepsy is expected to reach up to XXX cases by the end of 2025 at a CAGR of 4.13% from 2015-2025. High prevalent cases were observed in United States as compared to EU5 and Japan.

The market is dominated by approved therapies that are used for the treatment of
Epilepsy. The three best selling drugs of 2016 were Vimpat (UCB), Lamictal (Glaxosmithkline) and Keppra (UCB).

United States contributes the major share of Epilepsy market as compared to EU5 countries and Japan. The therapeutic market of Epilepsy in 7MM is expected to reach USD 8.8 Billion in 2025 at the CAGR of XX% from 2015-2025.

Key Coverage and Benefits:
The report will help in developing business strategies by understanding the trends shaping and driving the Epilepsy market in 7MM.
Organize sales and marketing efforts by identifying the best opportunities for Epilepsy in US, European Union 5 (Germany, Spain, Italy, France and United Kingdom) and Japan.
To understand the future competition in the Epilepsy market (7MM) and Insightful review of the key market drivers and barriers.
The report provides historical as well as forecasted epidemiology of Epilepsy in the 7MM covering United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan from 2015-2025.
The Report also covers the detailed historical and forecasted Epilepsy market covering United States, European Union 5 (EU5-Germany, Spain, Italy, France and United Kingdom), Japan and Rest of the World (RoW) from 2015-2025.
1. Report Summary
2. Epilepsy Disease Background
2.1. Introduction
2.2. Causes
2.3. Symptoms
2.4. Classification
2.5. Risk factors
2.6. Diagnosis
2.7. TSC Mutations in Epilepsy
2.8. Current Treatment & Medical Practices
3. Epidemiology and Patient Population
3.1. Key Points:
4. United States
4.1. Prevalence of Epilepsy in United States
4.2. Gender specific prevalence in United States
4.3. Sub-type specific prevalence in United States
4.4. Prevalence of TSC associated Epilepsy in the United States
5. Germany
5.1. Prevalence of Epilepsy in Germany
5.2. Gender specific prevalence in Germany
5.3. Sub-type specific prevalence in Germany
5.4. Prevalence of TSC associated Epilepsy in the Germany
6. France
6.1. Prevalence of Epilepsy in France
6.2. Gender specific prevalence in France
6.3. Sub-type specific prevalence in France
6.4. Prevalence of TSC associated Epilepsy in the France
7. Italy
7.1. Prevalence of Epilepsy in Italy
7.2. Gender specific prevalence in Italy
7.3. Sub-type specific prevalence in Italy
7.4. Prevalence of TSC associated Epilepsy in the Italy
8. Spain
8.1. Prevalence of Epilepsy in Spain
8.2. Gender specific prevalence in Spain
8.3. Sub-type specific prevalence in Spain
8.4. Prevalence of TSC associated Epilepsy in the Spain
9. United Kingdom
9.1. Prevalence of Epilepsy in United Kingdom
9.2. Gender specific prevalence in United Kingdom
9.3. Sub-type specific prevalence in United Kingdom
9.4. Prevalence of TSC associated Epilepsy in the UK
10. Japan
10.1. Prevalence of Epilepsy in Japan
10.2. Gender specific prevalence in Japan
10.3. Sub-type specific prevalence in Japan
11. Treatment Algorithm
11.1. NICE Guidelines
11.2. Treatment options in the management of Epilepsy in patients with TSC
11.3. Epilepsy treatment in TSC: Clinical Recommendations
12. Unmet Needs
13. Competitive Landscape-Marketed Drugs
13.1. Vimpat: UCB
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Vimpat Sales
13.2. Lyrica: Pfizer
13.2.1. Drug Description
13.2.2. Product Profile
13.2.3. Lyrica Sales
13.3. Banzel: Eisai
13.3.1. Drug Description
13.3.2. Product Profile
13.3.3. Banzel Sales
13.4. Briviact: UCB Pharma
13.4.1. Drug Description
13.4.2. Product Profile
13.4.3. Briviact Sales
13.5. Keppra: UCB
13.5.1. Drug Description
13.5.2. Product Profile
13.5.3. Keppra Sales
13.6. Keppra XR (levetiracetam XR): UCB
13.6.1. Drug Description
13.6.2. Product Profile
13.6.3. Keppra Sales
13.7. Topamax: Janssen
13.7.1. Drug Production
13.7.2. Product Profile
13.7.3. Topamax Sales
13.8. Lamictal: GlaxoSmithKline
13.8.1. Drug Description
13.8.2. Product Profile
13.8.3. Lamictal Sales
13.9. Neurontin: Pfizer
13.9.1. Drug Description
13.9.2. Product Profile
13.9.3. Neurontin Sales
13.10. Zonegran: Eisai
13.10.1. Drug Description
13.10.2. Product Profile
13.10.3. Zonegran Sales
13.11. Trileptal: Novartis
13.11.1. Drug Description
13.11.2. Product Profile
13.11.3. Trileptal Sales
13.12. Zebinix (Aptiom): Dainippon Sumitomo Pharma/Eisai
13.12.1. Drug Description
13.12.2. Product Profile
13.12.3. Zebinix (Aptiom) Sales
13.13. Fycompa: Eisai
13.13.1. Drug Description
13.13.2. Product Profile
13.13.3. Fycompa Sales
14. Emerging Therapies
14.1. Upcoming Drugs
15. Epidiolex: GW Pharmaceuticals
15.1. Product Description
15.2. Research and Development
15.3. Product Development Activities
16. Fintepla: Zogenix
16.1. Product Description
16.2. Research and Development
16.3. Product Development Activities
17. PF-06372865: Pfizer
17.1. Product Description
17.2. Research & Development
18. UCB0942: UCB
18.1. Product Description
18.2. Research & Development
19. Ganaxolone: Marinus Pharmaceuticals
19.1. Product Description
19.2. Research & Development
19.3. Product Development Activities
20. SAGE-547: Sage Therapeutics
20.1. Product Description
20.2. Research and Development
20.3. Product Development Activities
21. Triheptanoin: Ultragenyx Pharmaceutical
21.1. Product Description
21.2. Research and Development
21.3. Product Development Activities
22. CPP-115: Catalyst Pharmaceuticals
22.1. Product Description
22.2. Research and development
22.3. Product Development Activities
23. ZYN002: Zynerba Pharma
23.1. Product Description
23.2. Research and Development
23.3. Product Development Activities
24. Market Size of Epilepsy
25. Global Market Size
25.1. Key Findings
25.2. Market Size of Top-10 Products (2016)
25.3. Market Size of Top-10 Products (2025)
25.4. Upcoming Drug Launches-Uptake
26. United States
26.1. Market Outlook of Epilepsy in United States
27. EU5
27.1. Market outlook of Epilepsy in EU5
28. Japan
28.1. Market outlook of Epilepsy in Japan
29. Market Drivers
30. Market Barriers
31. Appendix
31.1. Report Methodology
32. Consulting Services
33. Disclaimer
34. About DelveInsight

List of Table

Table 1: Prevalent Population of Epilepsy in the United States (2015-2025)
Table 2: Gender specific Prevalent Population of Epilepsy in the United States (2015-2025)
Table 3: Sub-type specific Prevalent Population of Epilepsy in the United States (2015-2025)
Table 4: Prevalence of TSC associated Epilepsy in the United States (2015-2025)
Table 5: Prevalent Population of Epilepsy in the Germany (2015-2025)
Table 6: Gender specific Prevalent Population of Epilepsy in the Germany (2015-2025)
Table 7: Sub-type specific Prevalent Population of Epilepsy in the United States (2015-2025)
Table 8: Prevalence of TSC associated Epilepsy in the Germany (2015-2025)
Table 9: Prevalent Population of Epilepsy in the France (2015-2025)
Table 10: Gender specific Prevalent Population of Epilepsy in the France (2015-2025)
Table 11: Sub-type specific Prevalent Population of Epilepsy in the France (2015-2025)
Table 12: Prevalence of TSC associated Epilepsy in the France (2015-2025)
Table 13: Prevalent Population of Epilepsy in the Italy (2015-2025)
Table 14: Gender specific Prevalent Population of Epilepsy in the Italy (2015-2025)
Table 15: Sub-type specific Prevalent Population of Epilepsy in the Italy (2015-2025)
Table 16: Prevalence of TSC associated Epilepsy in the Italy (2015-2025)
Table 17: Prevalent Population of Epilepsy in the Spain (2015-2025)
Table 18: Gender specific Prevalent Population of Epilepsy in the Spain (2015-2025)
Table 19: Sub-type specific Prevalent Population of Epilepsy in the Spain (2015-2025)
Table 20: Prevalence of TSC associated Epilepsy in the Spain (2015-2025)
Table 21: Prevalent Population of Epilepsy in the United Kingdom (2015-2025)
Table 22: Gender specific Prevalent Population of Epilepsy in the UK (2015-2025)
Table 23: Sub-type specific Prevalent Population of Epilepsy in the UK (2015-2025)
Table 24: Prevalence of TSC associated Epilepsy in the UK (2015-2025)
Table 25: Prevalent Population of Epilepsy in the Japan (2015-2025)
Table 26: Gender specific Prevalent Population of Epilepsy in the Japan (2015-2025)
Table 27: Sub-type specific Prevalent Population of Epilepsy in the Japan (2015-2025)
Table 28: Upcoming therapies and their launch dates (2015-2025)
Table 29: Global Market Size of Epilepsy in USD, Million (2015-2025)
Table 30: Market Size of Top-10 Products (2016)
Table 31: Market Size of Top-10 Products (2025)
Table 32: Upcoming Drug Launches-Uptake Graph (2015-2025)
Table 33: United States Market Size of Epilepsy in USD, Million (2015-2025)
Table 34: EU5 Market Size of Epilepsy in USD, Million (2015-2025)
Table 35:Japan Market Size of Epilepsy in USD, Million (2015-2025)

List of Chart

Figure 1: ILAE 2017 Classification of Seizure Types Basic Version
Figure 2: ILAE 2017 Classification of Seizure Types Extended Version
Figure 3: Classification of Epilepsy
Figure 4: Prevalent Population of Epilepsy in the United States (2015-2025)
Figure 5: Gender specific Prevalent Population of Epilepsy in the United States (2015-2025)
Figure 6: Sub-type specific Prevalent Population of Epilepsy in the United States (2015-2025)
Figure 7: Prevalence of TSC associated Epilepsy in the United States (2015-2025)
Figure 8: Prevalent Population of Epilepsy in the Germany (2015-2025)
Figure 9: Gender specific Prevalent Population of Epilepsy in the Germany (2015-2025)
Figure 10: Sub-type specific Prevalent Population of Epilepsy in the Germany (2015-2025)
Figure 11: Prevalence of TSC associated Epilepsy in the Germany (2015-2025)
Figure 12: Prevalent Population of Epilepsy in the France (2015-2025)
Figure 13: Gender specific Prevalent Population of Epilepsy in the France (2015-2025)
Figure 14: Sub-type specific Prevalent Population of Epilepsy in the France (2015-2025)
Figure 15: Prevalence of TSC associated Epilepsy in the France (2015-2025)
Figure 16: Prevalent Population of Epilepsy in the Italy (2015-2025)
Figure 17: Gender specific Prevalent Population of Epilepsy in the Italy (2015-2025)
Figure 18: Sub-type specific Prevalent Population of Epilepsy in the Italy (2015-2025)
Figure 19: Prevalence of TSC associated Epilepsy in the Italy (2015-2025)
Figure 20: Prevalent Population of Epilepsy in the Spain (2015-2025)
Figure 21: Gender specific Prevalent Population of Epilepsy in the Spain (2015-2025)
Figure 22: Sub-type specific Prevalent Population of Epilepsy in the Spain (2015-2025)
Figure 23: Prevalence of TSC associated Epilepsy in the Spain (2015-2025)
Figure 24: Prevalent Population of Epilepsy in the United Kingdom (2015-2025)
Figure 25: Gender specific Prevalent Population of Epilepsy in the UK (2015-2025)
Figure 26: Sub-type specific Prevalent Population of Epilepsy in the UK (2015-2025)
Figure 27: Prevalence of TSC associated Epilepsy in the UK (2015-2025)
Figure 28: Prevalent Population of Epilepsy in the Japan (2015-2025)
Figure 29: Gender specific Prevalent Population of Epilepsy in the Japan (2015-2025)
Figure 30: Sub-type specific Prevalent Population of Epilepsy in the Japan (2015-2025)
Figure 31: Seizure-Types and Choice of Anti-Epileptic Drugs (AEDs)
Figure 32: Vimpat: Historical Sales (2012-2016)
Figure 33: Lyrica: Historical Sales (2012-2016)
Figure 34: Banzel: Historical Sales (2012-2016)
Figure 35:: Keppra: Historical Sales (2012-2016)
Figure 36: Keppra: Historical Sales (2012-2016)
Figure 37: Topamax: Historical Sales (2012-2016)
Figure 38:: Lamictal: Historical Sales (2012-2016)
Figure 39: Neurontin: Historical Sales (2012-2016)
Figure 40: Zonegran: Historical Sales (2012-2016)
Figure 41: Trileptal: Historical Sales (2012-2016)
Figure 42: Zebinix: Historical Sales (2012-2016)
Figure 43: Fycompa: Historical Sales (2012-2016)
Figure 44: Global Market size of Epilepsy in USD, Millions (2015-2025)
Figure 45: Market Size of Top-10 Products (2016)
Figure 46: Market Size of Top-10 Products (2025)
Figure 47: Upcoming Drug Launches-Uptake Graph (2015-2025)
Figure 48: United States Market size of Epilepsy in USD, Millions (2015-2025)
Figure 49: EU5 Market size of Epilepsy in USD, Millions (2015-2025)
Figure 50:Japan Market size of Epilepsy in USD, Millions (2015-2025)

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *